Celldex's barzolvolimab fails Phase 2 trial in prurigo nodularis

July 21, 2026 4:01 PM

Celldex Therapeutics (NASDAQ: CLDX) reported that its Phase 2 study of barzolvolimab in prurigo nodularis (PN) did not meet its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found